Plus, news about Pfizer’s tilrekimig, Gilead-Arcellx deal, Dianthus Therapeutics, NovaBridge, Relmada Therapeutics, Ideaya, Rapport Therapeutics, Bristol Myers Squibb’s Sotyktu:
💉 AbbVie, Gubra’s long-acting amylin shows promise in early-stage trial:


